
|Videos|October 11, 2016
CASE 4: 52-Year-Old Man with Relapsed Metastatic NSCLC
Advertisement
Jonathan W. Riess, MD, MS:
Riess case 4:
52-year-old man with relapsed metastatic NSCLC.
- 52-year-old man developed NSCLC, metastatic to the bone and brain
- Was found to have an EGFR activating mutation
- Started on erlotinib with a good response, received radiotherapy to hip and brain
- After 12 months he developed cough and dyspnea on exertion
- CT scan showed progression in the primary lesion and multiple other pulmonary nodules
- Tissue biopsy showed an EGFR T790M mutation
- Subsequent treatment with osimertinib resulted in tumor shrinkage as well as resolution of his symptoms.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
FDA Grants FTD to GPRC5D Bispecific LBL-034 for R/R Multiple Myeloma
4
Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer
5

















